SCHEMBL8962550

SCHEMBL8962550

CCOC(=O)CS(=O)(=O)Nc1c(C(C)C)cccc1C(C)C

nearest known ligand 0.58

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
NLRP3 Q96P20 3/20 0.58
MAPK1 P28482 1/20 0.47
GAA P10253 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8962687 0.85
SCHEMBL8962380 0.81 LMNA (0.47)
SCHEMBL8962531 0.81 SMN1; SMN2 (0.47)
SCHEMBL9390816 0.80 SMN1; SMN2 (0.50)
SCHEMBL8962730 0.79
SCHEMBL2147884 0.78 NLRP3 (0.70) NLRP3MAPK1
SCHEMBL8962535 0.78 SMN1; SMN2 (0.60)
SCHEMBL9059564 0.78 SOAT2 (0.46)
SCHEMBL11267236 0.77 NLRP3 (0.63) NLRP3MAPK1
SCHEMBL8962536 0.77 SOAT1 (0.44)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-1996019446-A1 β-CARBOXY SULFONAMIDE ACAT INHIBITORS WARNER-LAMBERT COMPANY (US) 1996-06-27 WO disclosed
US-5491170-A TREATMENT OF HYPERCHOLESTEROLEMIA AND ATHEROSCLEROSIS WARNER-LAMBERT COMPANY (US) 1996-02-13 US disclosed